Literature DB >> 20034648

Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response.

Katherine A Bosch1, Stephanie Rainwater, Walter Jaoko, Julie Overbaugh.   

Abstract

The origin of broadly neutralizing HIV-specific antibodies and their relation to HIV evolution are not well defined. Here we examined virus evolution and neutralizing antibody escape in a subtype A infected individual with a broad, cross subtype, antibody response. The majority of envelope variants isolated over the first approximately 5 years after infection were poorly neutralized by contemporaneous plasma that neutralized variants from earlier in infection, consistent with a dynamic process of escape. The majority of variants could be neutralized by later plasma, suggesting these evolving variants may have contributed to the elicitation of new antibody responses. However, some variants from later in infection were recognized by plasma from earlier in infection, including one notably neutralization-sensitive variant that was sensitive due to a proline at position 199 in V2. These studies suggest a complex pattern of virus evolution in this individual with a broad NAb response, including persistence of neutralization-sensitive viruses. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20034648      PMCID: PMC2823950          DOI: 10.1016/j.virol.2009.11.032

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  54 in total

1.  Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency.

Authors:  J Albert; A Nauclér; B Böttiger; P A Broliden; P Albino; S A Ouattara; C Björkegren; A Valentin; G Biberfeld; E M Fenyö
Journal:  AIDS       Date:  1990-04       Impact factor: 4.177

2.  The neighbor-joining method: a new method for reconstructing phylogenetic trees.

Authors:  N Saitou; M Nei
Journal:  Mol Biol Evol       Date:  1987-07       Impact factor: 16.240

3.  HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus.

Authors:  E Michelle Long; Stephanie M J Rainwater; Ludo Lavreys; Kishorchandra Mandaliya; Julie Overbaugh
Journal:  AIDS Res Hum Retroviruses       Date:  2002-05-20       Impact factor: 2.205

4.  A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences.

Authors:  M Kimura
Journal:  J Mol Evol       Date:  1980-12       Impact factor: 2.395

5.  A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.

Authors:  Martin Markowitz; Michael Louie; Arlene Hurley; Eugene Sun; Michele Di Mascio; Alan S Perelson; David D Ho
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission.

Authors:  Christine M Rousseau; Ruth W Nduati; Barbra A Richardson; Grace C John-Stewart; Dorothy A Mbori-Ngacha; Joan K Kreiss; Julie Overbaugh
Journal:  J Infect Dis       Date:  2004-10-07       Impact factor: 5.226

8.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

9.  Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.

Authors:  Ludo Lavreys; Jared M Baeten; Joan K Kreiss; Barbra A Richardson; Bhavna H Chohan; Wisal Hassan; Dana D Panteleeff; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  J Infect Dis       Date:  2004-01-09       Impact factor: 5.226

10.  Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

Authors:  Hector R Rangel; Jan Weber; Bikram Chakraborty; Arantxa Gutierrez; Michael L Marotta; Muneer Mirza; Patti Kiser; Miguel A Martinez; Jose A Este; Miguel E Quiñones-Mateu
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more
  19 in total

1.  The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter.

Authors:  Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

Review 2.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency.

Authors:  Sandra D Taylor; Steven R Leib; Wuwei Wu; Robert Nelson; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

4.  Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.

Authors:  Samantha Townsley; Yun Li; Yury Kozyrev; Brad Cleveland; Shiu-Lok Hu
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

5.  Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Authors:  Franco Pissani; Delphine C Malherbe; Harlan Robins; Victor R DeFilippis; Byung Park; George Sellhorn; Leonidas Stamatatos; Julie Overbaugh; Nancy L Haigwood
Journal:  Vaccine       Date:  2012-06-27       Impact factor: 3.641

6.  Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120.

Authors:  Thaddeus M Davenport; Miklos Guttman; Wenjin Guo; Brad Cleveland; Maria Kahn; Shiu-Lok Hu; Kelly K Lee
Journal:  J Virol       Date:  2013-07-31       Impact factor: 5.103

7.  Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.

Authors:  David F Boyd; Dylan Peterson; Beth S Haggarty; Andrea P O Jordan; Michael J Hogan; Leslie Goo; James A Hoxie; Julie Overbaugh
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

8.  Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.

Authors:  Xueling Wu; Charlene Wang; Sijy O'Dell; Yuxing Li; Brandon F Keele; Zhongjia Yang; Hiromi Imamichi; Nicole Doria-Rose; James A Hoxie; Mark Connors; George M Shaw; Richard T Wyatt; John R Mascola
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

9.  Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  Reza Sadjadpour; Olivia K Donau; Masashi Shingai; Alicia Buckler-White; Sandra Kao; Klaus Strebel; Yoshiaki Nishimura; Malcolm A Martin
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

10.  Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.

Authors:  Megan K Murphy; Ling Yue; Ruimin Pan; Saikat Boliar; Anurag Sethi; Jianhui Tian; Katja Pfafferot; Etienne Karita; Susan A Allen; Emmanuel Cormier; Paul A Goepfert; Persephone Borrow; James E Robinson; S Gnanakaran; Eric Hunter; Xiang-Peng Kong; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2013-02-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.